• Electra Therapeutics reported a third-quarter 2026 net loss of $23.9 million.
• Research and development expenses totaled $17.3 million, while general and administrative expenses reached $7.8 million.
• Cash, cash equivalents and marketable securities totaled $402.5 million at September 30, 2026, with planned operations funded into 2029.
• ELA822 healthy-volunteer data are expected in first-half 2027, with enrollment completion for ipsoprubart’s sHLH registrational program expected in the second half.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Electra Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611121601PRIMZONEFULLFEED9876799) on November 12, 2026, and is solely responsible for the information contained therein.